Canada markets closed

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.89-0.20 (-2.82%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close7.09
Open6.96
Bid6.95 x 900
Ask7.00 x 1000
Day's Range6.80 - 7.14
52 Week Range1.40 - 30.10
Volume803,839
Avg. Volume1,373,988
Market Cap157.328M
Beta (5Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-1.99
Earnings DateAug. 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.25
  • ACCESSWIRE

    Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

    DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B.

  • ACCESSWIRE

    Heat Biologics Commences Manufacturing Process for ZVX-60

    DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc.Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials.

  • ACCESSWIRE

    Heat Biologics Promotes William L. Ostrander to Chief Financial Officer

    DURHAM, NC / ACCESSWIRE / January 11, 2021 /Heat Biologics, Inc. ("Heat")(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021.